Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial.

BACKGROUND AND AIMS Fentanyl is primarily responsible for the current phase of the overdose epidemic in North America. Despite the benefits of treatment with medications for opioid use disorder (MOUD), there are limited data on the association between fentanyl, MOUD type and treatment engagement. The objectives of this analysis were to measure the impact of baseline fentanyl exposure on initiation and discontinuation of MOUD among individuals with prescription-type opioid use disorder (POUD). DESIGN, SETTING AND PARTICIPANTS Secondary analysis of a Canadian multi-site randomized pragmatic trial conducted between 2017 and 2020. Of the 269 randomized participants, 65.4% were male, 67.3% self-identified as white and 55.4% had a positive fentanyl urine drug test (UDT) at baseline. Fentanyl-exposed participants were more likely to be younger, to self-identify as non-white, to be unemployed or homeless and to be currently using stimulants than non-fentanyl-exposed participants. INTERVENTIONS Flexible take-home dosing buprenorphine/naloxone or supervised methadone models of care for 24 weeks. MEASUREMENTS Outcomes were (1) MOUD initiation and (2) time to (a) assigned and (b) overall MOUD discontinuation. Independent variables were baseline fentanyl UDT (predictor) and assigned MOUD (effect modifier). FINDINGS Overall, 209 participants (77.7%) initiated MOUD. In unadjusted analyses, fentanyl exposure was associated with reduced likelihood of treatment initiation [odds ratio (OR) = 0.18, 95% confidence interval (CI) = 0.08-0.36] and shorter median times in assigned [20 versus 168 days, hazard ratio (HR) = 3.61, 95% CI = 2.52-5.17] and any MOUD (27 versus 168 days, HR = 3.32, 95% CI = 2.30-4.80). The negative effects were no longer statistically significant in adjusted models, and no interaction between fentanyl and MOUD was observed for any of the outcomes (all P > 0.05). CONCLUSIONS Both buprenorphine/naloxone and methadone may be appropriate treatment options for people with prescription-type opioid use disorder regardless of fentanyl exposure. Other characteristics of fentanyl-exposed individuals appear to be driving the association with poorer treatment outcomes.

[1]  T. Wild,et al.  Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial. , 2022, The American journal of psychiatry.

[2]  P. Korthuis,et al.  Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease. , 2021, Drug and alcohol dependence.

[3]  E. Wood,et al.  Increasing Preference for Fentanyl among A Cohort of People who Use Opioids in Vancouver, Canada, 2017-2018 , 2021, Substance abuse.

[4]  K. Zivin,et al.  Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018. , 2021, JAMA.

[5]  P. Bain,et al.  Opioid use disorder treatment for people experiencing homelessness: A scoping review , 2021, Drug and alcohol dependence.

[6]  M. Cerdá,et al.  Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings. , 2021, Journal of substance abuse treatment.

[7]  E. Wood,et al.  Cannabis use is associated with reduced risk of exposure to fentanyl among people on opioid agonist therapy during a community-wide overdose crisis. , 2020, Drug and alcohol dependence.

[8]  L. Thabane,et al.  Treatment Outcomes in Patients With Opioid Use Disorder Who Were First Introduced to Opioids by Prescription: A Systematic Review and Meta-Analysis , 2020, Frontiers in Psychiatry.

[9]  F. Boland,et al.  Retention of patients in opioid substitution treatment: A systematic review , 2020, PloS one.

[10]  A. Slaunwhite,et al.  Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study , 2020, BMJ.

[11]  J. Gryczynski,et al.  Fentanyl exposure and preferences among individuals starting treatment for opioid use disorder. , 2019, Drug and alcohol dependence.

[12]  C. Cahill,et al.  Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment , 2019, Neuroscience & Biobehavioral Reviews.

[13]  T. Cicero,et al.  Twin epidemics: The surging rise of methamphetamine use in chronic opioid users. , 2018, Drug and alcohol dependence.

[14]  J. Rich,et al.  Methadone maintenance treatment among patients exposed to illicit fentanyl in Rhode Island: Safety, dose, retention, and relapse at 6 months. , 2018, Drug and alcohol dependence.

[15]  Brandon D. L. Marshall,et al.  The Deepening Opioid Crisis in North America: Historical Context and Current Solutions , 2018, Current Addiction Reports.

[16]  E. Wood,et al.  The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale. , 2018, Contemporary clinical trials.

[17]  Evan Wood,et al.  Management of opioid use disorders: a national clinical practice guideline , 2018, Canadian Medical Association Journal.

[18]  Benjamin P Linas,et al.  Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. , 2018, Journal of substance abuse treatment.

[19]  E. Wood,et al.  Substance use patterns associated with recent exposure to fentanyl among people who inject drugs in Vancouver, Canada: A cross-sectional urine toxicology screening study. , 2018, Drug and alcohol dependence.

[20]  L. Degenhardt,et al.  Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies , 2017, British Medical Journal.

[21]  S. Nielsen,et al.  Opioid agonist treatment for pharmaceutical opioid dependent people. , 2016, The Cochrane database of systematic reviews.

[22]  C. Timko,et al.  Retention in medication-assisted treatment for opiate dependence: A systematic review , 2016, Journal of addictive diseases.

[23]  Pavel S. Roshanov,et al.  Usefulness of the Brief Pain Inventory in Patients with Opioid Addiction Receiving Methadone Maintenance Treatment. , 2016, Pain physician.

[24]  J. Montaner,et al.  A call for evidence-based medical treatment of opioid dependence in the United States and Canada. , 2013, Health affairs.

[25]  D. Moher,et al.  Improving the reporting of pragmatic trials: an extension of the CONSORT statement , 2008, BMJ : British Medical Journal.

[26]  J. Schmitz,et al.  Factor structure and diagnostic efficiency of the BDI-II in treatment-seeking substance users. , 2008, Drug and alcohol dependence.

[27]  R P Mattick,et al.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. , 2008, The Cochrane database of systematic reviews.

[28]  R. Moos,et al.  Consistency of self-administered and interview-based Addiction Severity Index composite scores. , 2000, Addiction.

[29]  S. Greenland,et al.  Simulation study of confounder-selection strategies. , 1993, American journal of epidemiology.